Inspire Medical Systems (INSP)
(Delayed Data from NYSE)
$190.71 USD
-4.33 (-2.22%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $190.90 +0.19 (0.10%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$190.71 USD
-4.33 (-2.22%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $190.90 +0.19 (0.10%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Zacks News
Boston Scientific (BSX) Q1 Earnings Beat Estimates, View Raised
by Zacks Equity Research
Barring Neuromodulation, organic and operational revenues at Boston Scientific's (BSX) core business segments rise in the first quarter.
Quest Diagnostics (DGX) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Quest Diagnostics (DGX) continues its strong momentum of base business revenue growth in the first quarter of 2024.
Should You Buy STERIS (STE) Stock Ahead of Q4 Earnings?
by Zacks Equity Research
STERIS (STE) is expected to have witnessed the normalization of the Healthcare backlog, as the company is currently able to ship at a faster pace than the receipt of new orders.
Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aldeyra Therapeutics, Inc. (ALDX) and Inspire Medical Systems (INSP) have performed compared to their sector so far this year.
What's in the Cards for Zimmer Biomet (ZBH) in Q1 Earnings?
by Zacks Equity Research
Within the Hips business, Zimmer Biomet (ZBH) is expected to have witnessed procedure volume recovery, banking on strategic product launches in the first quarter.
Will Humana (HUM) Q1 Earnings Beat on CenterWell Strength?
by Zacks Equity Research
Humana's (HUM) first-quarter results are likely to reflect rising premiums and investment income.
What Lies Ahead of IDEXX Laboratories (IDXX) in Q1 Earnings?
by Zacks Equity Research
IDEXX Laboratories' (IDXX) first-quarter 2024 results are likely to reflect the benefits of strong execution against the growth strategy.
Here's Why You Should Retain Prestige Consumer (PBH) Stock Now
by Zacks Equity Research
The robust strength of Prestige Consumer's (PBH) diversified portfolio bodes well for investors.
Will High Medical Care Ratios Hurt Molina's (MOH) Q1 Earnings?
by Zacks Equity Research
Molina's (MOH) first-quarter performance is likely to have been hurt by escalating medical care costs, partly offset by growing membership in all three businesses.
Why You Should Add Inspire Medical (INSP) to Your Portfolio
by Zacks Equity Research
Inspire Medical's (INSP) focus on R&D raises optimism about the stock.
Will Low Patient Days Impact Community Health (CYH) Q1 Earnings?
by Zacks Equity Research
Community Health's (CYH) first-quarter results are likely to reflect declining beds in services and adjusted admissions.
ICON (ICLR) Gains From New Offerings, Strategic Acquisitions
by Zacks Equity Research
ICON (ICLR) continues to develop its collaboration and delivery models, invest in technology and enhance its project and program management capabilities.
CVS Health (CVS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
The strength of a diversified enterprise, along with robust operational execution, is expected to be reflected in CVS Health's (CVS) first-quarter 2024 results.
Inspire (INSP) Surges 9.9%: Is This an Indication of Further Gains?
by Zacks Equity Research
Inspire (INSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Abbott (ABT) Q1 Earnings Beat Estimates, Margins Contract
by Zacks Equity Research
Abbott (ABT) delivers double-digit organic sales growth in its underlying base business in the first quarter of 2024.
Here's Why You Should Retain Henry Schein (HSIC) Stock for Now
by Zacks Equity Research
Favorable Dental business trends and expansion efforts through acquisitions and partnerships bode well for Henry Schein (HSIC).
UnitedHealth Group (UNH) Tops on Q1 Earnings, Reaffirms EPS View
by Zacks Equity Research
UnitedHealth Group (UNH) first-quarter earnings benefit from strong Optum and UnitedHealthcare business lines. Rising expenses partially offset the positives.
Labcorp (LH) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Labcorp (LH) is anticipated to drive growth in the first quarter of 2024 through base business expansion, integrating acquisitions and partnerships and advancing in science and technology.
Will Elevance (ELV) Beat Q1 Earnings on Carelon Strength?
by Zacks Equity Research
The first-quarter results of Elevance (ELV) are likely to reflect higher product revenues and Commercial Individual membership growth.
Quest Diagnostics (DGX) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Acquisitions and partnerships with health plans are expected to drive Quest Diagnostics' (DGX) base business performance in the first quarter of 2024.
Can High Medical Costs Affect UnitedHealth's (UNH) Q1 Earnings?
by Zacks Equity Research
UnitedHealth's (UNH) first-quarter results are likely to reflect growth in premium levels and service revenues.
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Will UnitedHealth's (UNH) UnitedHealthcare Unit Aid Q1 Earnings?
by Zacks Equity Research
UnitedHealth's (UNH) first-quarter results are expected to benefit from an increase in UnitedHealthcare's Community & State revenues and the number of people it served.
New Strong Buy Stocks for April 9th
by Zacks Equity Research
SRDX, X, TELNY, INSP and MTAL have been added to the Zacks Rank #1 (Strong Buy) List on April 9, 2023.
3 Medical Info Systems Stocks to Buy as Industry Improves
by Urmimala Biswas
A few Zacks Medical Info Systems industry stocks like Inspire Medical Systems (INSP), Talkspace (TALK) and Health Catalyst (HCAT) are expected to gain from the new normal trends.